Table: q1_q4_2019_prescription_drugs_wac_increases , manufacturer_name like H*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000144	Helsinn Therapeutics, Inc	09/30/2019	69639012001	Valchlor 0.02% Gel 60gm tube	09/26/2019	273.68	4183.46	07/08/2029	Single Source Drug	8575	None	The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications.	None	None	1	03/20/2018	Actelion Pharmaceuticals, Ltd.	330000000	None	None	3654.00	3355.00	2013	3165.00	None	None
Rx0000119	Heron Therapeutics, Inc.	12/31/2019	47426020101	CINVANTI; 130 mg; single-dose vial	10/01/2019	7.72	351.47	None	Single Source Drug	278108	None	Increase due to market factors	None	There were no noted changes to the drug.	None	None	None	None	None	None	None	None	None	None	None	Product was developed by Heron
Rx0000119	Heron Therapeutics, Inc.	06/30/2019	47426010106	Granisetron extended-release injection	06/01/2019	90.42	3706.86	None	Single Source Drug	14393	None	Increase due to market factors.	None	There were no noted changes to the drug.	None	None	None	None	None	None	None	None	None	None	None	Product was developed by Heron
Rx0000119	Heron Therapeutics, Inc.	12/31/2019	47426010106	Sustol (granisetron) ER injection. 10 mg/.4mL. 6 kits/carton.	12/15/2019	92.67	3799.53	None	Single Source Drug	14393	None	Increase due to market factors.	None	There were no noted changes to the drug.	None	None	None	None	None	None	None	None	None	None	None	Product was developed by Heron
Rx0000178	Hikma Pharmaceuticals USA Inc	03/31/2019	00143978710	Enalaprilat Intravenous Injectable 1.25 MG/1ML, 10 Vials	01/01/2019	9.23	40.00	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	03/31/2019	00143978610	Enalaprilat Intravenous Injectable 1.25 MG/2ML, 10 Vials	01/01/2019	16.49	71.44	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2019	00641039112	Heparin Sodium (Porcine) Injection Solution 1000 UNIT/ML. 25 Vials	07/12/2019	17.05	51.15	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2019	00641246055	Heparin Sodium (Porcine) Injection Solution 5000 UNIT/ML, 25 Vials	07/12/2019	41.15	210.00	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	03/31/2019	00641605425	Meperidine HCl Injection Solution 100 MG/ML, 25 Vials	01/01/2019	5.93	65.87	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	03/31/2019	00641605225	Meperidine HCl Injection Solution 25 MG/ML, 25 Vials	01/01/2019	5.20	57.70	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	03/31/2019	00641605325	Meperidine HCl Injection Solution 50 MG/ML, 25 Vials	01/01/2019	5.41	60.10	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2019	00054021125	Protriptyline HCl Oral Tablet 10 MG, 100 Tablets	09/06/2019	232.75	477.75	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2019	00054021025	Protriptyline HCl Oral Tablet 5 MG, 100 Tablets	09/06/2019	232.75	477.75	None	Non-innovator Multiple Source Drug	None	1	None	1	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000145	Horizon Therapeutics USA, Inc.	09/30/2019	75987008010	Drug product name: KRYSTEXXA. Drug product strength: 1 mL sterile concentrate for dilution containing 8 mg of pegloticase protein, expressed in uricase protein amounts. Drug product dosage form: vial. Drug product package size: 2 mL single use vial.	07/01/2019	1055.78	22602.00	None	Single Source Drug	None	1	None	1	None	1	01/13/2016	Crealta Holdings LLC	None	1	Horizon acquired this particular product as part of the overall acquisition of Crealta Holdings LLC, and its acquisition price was incorporated into that deal’s overall purchase price of approximately $510 million with no means of individually identifying the purchase price of this asset.	14000.00	14000.00	2010	2300.00	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Please note the Patent Expiration date for KRYSTEXXA is not publicly available.